Evidence map›Paper›PMID 41882317›Full record

ArticleScience China. Life sciences2026

SIRT6 alleviates ischemic injury via orchestrating the RREB1/Snail and STC1/Smad7 signaling pathways to regulate endothelial-mesenchymal transition.

Zhentao Zhang, Zheyan Fang, Shuang Zhao, Mukaddas Abdurahman, Gang Zhao, Runyang Feng, Zhenyang Guo, Xueting Yu, Hangnan Hong, Jilong Geng and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Science China. Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Zhentao Zhang *Department of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, 200032, China.
Zheyan Fang *Department of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, 200032, China.
Shuang Zhao *Department of Medical Examination, Shanghai Xuhui District Central Hospital, Shanghai, 200031, China.
Mukaddas Abdurahman *Department of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, 200032, China.
Gang Zhao *Department of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, 200032, China.
Runyang FengDepartment of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, 200032, China.
Zhenyang GuoDepartment of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, 200032, China.
Xueting YuDepartment of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, 200032, China.
Hangnan HongDepartment of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, 200032, China.
Jilong GengDepartment of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, 200032, China.
Xiansu NieDepartment of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, 200032, China.
Supuya AbuduwahapiDepartment of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, 200032, China.
Lingyun LanDepartment of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, 200032, China.
Junbo GeDepartment of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, 200032, China. ge.junbo@zs-hospital.sh.cn.
Hua LiDepartment of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, Shanghai, 200032, China. lihua199988@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endothelial-to-mesenchymal transition (EndMT) constitutes a transdifferentiation phenomenon during which endothelial cells (ECs) progressively acquire mesenchymal traits. Mounting evidence has established that EndMT holds a central and indispensable position in angiogenesis. Partial EndMT, an intermediate stage of ECs within the EndMT cascade, is intimately regulated by numerous enzymes. Among them, sirtuin 6 (SIRT6), a member of the sirtuin family of NAD

Indexed as

DNA-Binding ProteinsEndothelial-Mesenchymal TransitionIschemiaSirtuinsTranscription FactorsAngiogenesisAnimalsEndothelial CellsHumansMaleMiceMice, Inbred C57BLSignal TransductionSmad7 ProteinSnail Family Transcription FactorsTransforming Growth Factor betaDNA-Binding ProteinsSirt6 protein, mouseSirtuinsSmad7 ProteinSmad7 protein, mouseSnail Family Transcription FactorsTranscription FactorsTransforming Growth Factor betaangiogenesisischemic injurypartial EndMTSirt6Smad

Identifiers

PMID41882317

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.